ReviewMedicine2026
Nephrotic syndrome in children: A review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrotic syndrome in children is a frequent glomerular disorder characterized by heavy proteinuria, hypoalbuminemia, edema, and dyslipidemia, most commonly caused by minimal change disease. Although corticosteroids remain the first-line therapy, variable treatment responses and the growing prevalence of steroid-resistant cases underscore the need for improved therapeutic strategies. The pathogenesis involves podocyte injury, immune dysregulation, and genetic susceptibility, highlighting the importance of early risk stratification. This review synthesizes current understanding of disease mechanisms, standard and emerging treatment options, and supportive care measures that mitigate complications such as infections, thromboembolism, and long-term renal impairment. By examining recent advances in biomarkers and precision medicine, the study aims to clarify how individualized treatment approaches can optimize outcomes while minimizing drug-related toxicity. A clearer understanding of evolving therapies and targeted podocyte-protective agents provides a foundation for future research and improved management of pediatric nephrotic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.